Egnyte Announces Solution for Trial Operations
Egnyte has announced Egnyte for Life Sciences eTMF, a product for the clinical development functions at life science companies to manage trial master file data. Egnyte for Life Sciences eTMF is 21 CFR Part 11 compliant solution that aims to reduce document processing time while maintaining compliance and audit readiness.
Egnyte for Life Sciences eTMF solution enables clinical development professionals to:
- Stay on track with milestones: built on Egnyte’s secure collaboration platform, get full visibility into study milestones, allowing clinical teams to communicate with sites to stick to timelines.
- Maintain control of trial information: Egnyte’s governance features allow teams to flag missing source documents, leverage AI and ML features for constant monitoring for misclassified documents or embedded PII/PHI.
- Be audit-ready and compliant: meeting GxP and FDA 21 CFR Part 11 requirements, Egnyte allows companies to stay audit-ready and maintain compliance in a cloud-based solution.
More about Egnyte for Life Sciences eTMF
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
